PD1 Antibody and Lenalidomide as a Treatment for EBV-HLH or CAEBV
Status:
Recruiting
Trial end date:
2021-07-01
Target enrollment:
Participant gender:
Summary
The present study was a prospective one-arm clinical study, in which EBV-HLH/chronic active
EBV infection patients were selected as the main subjects to evaluate the effect of PD-1
antibody and lenalidomide regimens on ebv-dna and safety.